{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:17:13Z","timestamp":1795112233059,"version":"4.10.3"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC-114-2314-B-567-002"],"award-info":[{"award-number":["NSTC-114-2314-B-567-002"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC-113-2314-B-567-001"],"award-info":[{"award-number":["NSTC-113-2314-B-567-001"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009974","name":"Cardinal Tien Hospital","doi-asserted-by":"publisher","award":["CTH-110A-2217"],"award-info":[{"award-number":["CTH-110A-2217"]}],"id":[{"id":"10.13039\/501100009974","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009974","name":"Cardinal Tien Hospital","doi-asserted-by":"publisher","award":["CTH-112A-2215"],"award-info":[{"award-number":["CTH-112A-2215"]}],"id":[{"id":"10.13039\/501100009974","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009974","name":"Cardinal Tien Hospital","doi-asserted-by":"publisher","award":["CTH-113A-NDMC-2233"],"award-info":[{"award-number":["CTH-113A-NDMC-2233"]}],"id":[{"id":"10.13039\/501100009974","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.biopha.2025.118881","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:10:21Z","timestamp":1770289821000},"page":"118881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Comparative effectiveness and safety landscape of anti-VEGF therapies for neovascular age-related macular degeneration: Insights from a systematic review and network meta-analysis"],"prefix":"10.1016","volume":"196","author":[{"given":"Kai-Yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi-Chun","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ming","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2025.118881_bib1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","article-title":"Comparison of Ranibizumab and Bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol","volume":"122","author":"Berg","year":"2015","journal-title":"Ophthalmology"},{"issue":"9900","key":"10.1016\/j.biopha.2025.118881_bib2","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"issue":"9900","key":"10.1016\/j.biopha.2025.118881_bib3","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118881_bib4","series-title":"Is retinal vein occlusion highly associated with an increased risk of myocardial infarction? A systematic review and meta-analysis","first-page":"86","author":"Chen","year":"2024"},{"issue":"6","key":"10.1016\/j.biopha.2025.118881_bib5","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.survophthal.2025.05.008","article-title":"Effectiveness and safety of anti-vascular endothelial growth factor therapies for macular edema in retinal vein occlusion: A systematic review and network meta-analysis of randomized controlled trials","volume":"70","author":"Chen","year":"2025","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.biopha.2025.118881_bib6","doi-asserted-by":"crossref","first-page":"112379","DOI":"10.1016\/j.diabres.2025.112379","article-title":"Which treatment modality offers the best outcomes for diabetic retinopathy? A systematic review and network meta-analysis","volume":"227","author":"Chen","year":"2025","journal-title":"Diabetes Res Clin Pr."},{"issue":"5","key":"10.1016\/j.biopha.2025.118881_bib7","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1007\/s12015-025-10884-x","article-title":"Can Stem Cell Therapy Revolutionize Ocular Disease Treatment? A Critical Review of Preclinical and Clinical Advances","volume":"21","author":"Chen","year":"2025","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.biopha.2025.118881_bib8","series-title":"Can artificial intelligence with multimodal imaging outperform traditional methods in predicting age-related macular degeneration progression? A systematic review and exploratory meta-analysis","first-page":"321","author":"Chen","year":"2025"},{"key":"10.1016\/j.biopha.2025.118881_bib9","doi-asserted-by":"crossref","first-page":"101389","DOI":"10.1016\/j.mam.2025.101389","article-title":"Unveiling the P2X7 receptor: Exploring its mechanisms, pathogenic role in ocular diseases, and emerging therapeutic potential","volume":"105","author":"Chen","year":"2025","journal-title":"Mol Asp. Med"},{"issue":"12","key":"10.1016\/j.biopha.2025.118881_bib10","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s40265-025-02237-2","article-title":"Can Gene Therapy Transform the Treatment Landscape of Posterior Segment Eye Diseases? A Comprehensive Review of Recent Advancements","volume":"85","author":"Chen","year":"2025","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.biopha.2025.118881_bib11","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s40123-025-01119-w","article-title":"Is Multiwavelength Photobiomodulation Effective and Safe for Age-Related Macular Degeneration? A Systematic Review and Meta-Analysis","volume":"14","author":"Chen","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.biopha.2025.118881_bib12","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions.\u201d n.d. Accessed November 7, 2023. \u3008https:\/\/training.cochrane.org\/handbook\u3009."},{"issue":"1","key":"10.1016\/j.biopha.2025.118881_bib13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of Brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.biopha.2025.118881_bib14","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s00417-020-05048-1","article-title":"Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) \u2014 a meta-analysis","volume":"259","author":"Garweg","year":"2021","journal-title":"Graefe\u2019S. Arch. Clin. Exp. Ophthalmol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118881_bib15","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","article-title":"Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial","volume":"137","author":"Gillies","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.biopha.2025.118881_bib16","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","article-title":"Effect of Ranibizumab and Aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial","volume":"137","author":"Gillies","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.biopha.2025.118881_bib17","series-title":"CADTH Health Technology Review","article-title":"Anti\u2013vascular endothelial growth factor drugs for age-related macular degeneration: CADTH health technology review","author":"Hao","year":"2023"},{"key":"10.1016\/j.biopha.2025.118881_bib18","series-title":"Comparison of Loading Dose between Aflibercept and Faricimab for Neovascular Age-Related Macular Degeneration","first-page":"385","author":"Hara","year":"2024"},{"issue":"oct18 2","key":"10.1016\/j.biopha.2025.118881_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"April","key":"10.1016\/j.biopha.2025.118881_bib20","article-title":"A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)","volume":"186","author":"Higgins","year":"2024","journal-title":"Environ. Int."},{"key":"10.1016\/j.biopha.2025.118881_bib21","unstructured":"Introduction to Age-Related Macular Degeneration - Treatments for Dry Age-Related Macular Degeneration and Stargardt Disease: A Systematic Review - NCBI Bookshelf.\u201d n.d. Accessed February 4, 2025. \u3008https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK500483\/\u3009."},{"issue":"8","key":"10.1016\/j.biopha.2025.118881_bib22","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"Tenaya and lucerne","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.biopha.2025.118881_bib23","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","article-title":"Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial","volume":"138","author":"Khanani","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"10.1016\/j.biopha.2025.118881_bib24","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","article-title":"Metaanalysis of real-world outcomes of intravitreal Ranibizumab for the treatment of neovascular age-related macular degeneration","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.biopha.2025.118881_bib25","series-title":"Methylglyoxal: A Key Factor for Diabetic Retinopathy and Its Effects on Retinal Damage","first-page":"2512","author":"Klochkov","year":"2024"},{"issue":"11","key":"10.1016\/j.biopha.2025.118881_bib26","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","article-title":"Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial","volume":"120","author":"Kodjikian","year":"2013","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.biopha.2025.118881_bib27","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/bjophthalmol-2012-302391","article-title":"A randomised double-masked trial comparing the visual outcome after treatment with Ranibizumab or Bevacizumab in patients with neovascular age-related macular degeneration","volume":"97","author":"Krebs","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.biopha.2025.118881_bib28","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1136\/bjophthalmol-2014-305302","article-title":"Safety profiles of anti-VEGF drugs: Bevacizumab, Ranibizumab, Aflibercept and Ziv-aflibercept on human retinal pigment epithelium cells in culture","volume":"98","author":"Malik","year":"2014","journal-title":"Br. J. Ophthalmol."},{"issue":"20","key":"10.1016\/j.biopha.2025.118881_bib29","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.biopha.2025.118881_bib30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00417-023-06241-8","article-title":"Comparison of functional and morphologic changes between Brolucizumab and Faricimab in neovascular age-related macular degeneration","volume":"262","author":"Maruyama-Inoue","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.biopha.2025.118881_bib31","series-title":"The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration","first-page":"2303","author":"Musia\u0142-Kopiejka","year":"2022"},{"key":"10.1016\/j.biopha.2025.118881_bib32","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"29","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.biopha.2025.118881_bib33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","article-title":"Vascular endothelial growth factor in eye disease","volume":"27","author":"Penn","year":"2008","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.biopha.2025.118881_bib34","series-title":"Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies","first-page":"1522","volume":"9","author":"Plyukhova","year":"2020"},{"key":"10.1016\/j.biopha.2025.118881_bib35","doi-asserted-by":"crossref","unstructured":"\u201cRanibizumab and bevacizumab for neovascular age-related macular degeneration.\u201d 2011. N. Engl. J. Med. 364 (20): 1897\u20131908. https:\/\/doi.org\/10.1056\/NEJMoa1102673.","DOI":"10.1056\/NEJMoa1102673"},{"issue":"1","key":"10.1016\/j.biopha.2025.118881_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ajo.2014.09.011","article-title":"Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen","volume":"159","author":"Rayess","year":"2015","journal-title":"Am. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118881_bib37","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3390\/ijms22031296","article-title":"Age-related macular degeneration: role of oxidative stress and blood vessels","volume":"22","author":"Ruan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118881_bib38","series-title":"Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration","first-page":"4041","author":"Rush","year":"2022"},{"issue":"9","key":"10.1016\/j.biopha.2025.118881_bib39","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","article-title":"Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial","volume":"138","author":"Sahni","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.biopha.2025.118881_bib40","series-title":"Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study","author":"Schauwvlieghe","year":"2016"},{"issue":"1","key":"10.1016\/j.biopha.2025.118881_bib41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal Aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"issue":"11\u201312","key":"10.1016\/j.biopha.2025.118881_bib42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00508-014-0539-z","article-title":"V\u00e9csei-Marlovits PV. Differences of frequency in administration of Ranibizumab and Bevacizumab in patients with neovascular AMD","volume":"126","author":"Scholler","year":"2014","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.biopha.2025.118881_bib43","series-title":"P2X7 Is Involved in the Mouse Retinal Degeneration via the Coordinated Actions in Different Retinal Cell Types","first-page":"141","volume":"12","author":"Sekar","year":"2023"},{"key":"10.1016\/j.biopha.2025.118881_bib44","doi-asserted-by":"crossref","first-page":"102786","DOI":"10.1016\/j.redox.2023.102786","article-title":"Metformin inhibits methylglyoxal-induced retinal pigment epithelial cell death and retinopathy via AMPK-dependent mechanisms: Reversing mitochondrial dysfunction and upregulating glyoxalase 1","volume":"64","author":"Sekar","year":"2023","journal-title":"Redox Biol"},{"issue":"1","key":"10.1016\/j.biopha.2025.118881_bib45","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ophtha.2015.09.002","article-title":"Intravitreal Bevacizumab versus Ranibizumab for treatment of neovascular age-related macular degeneration","volume":"123","author":"Solomon","year":"2016","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.biopha.2025.118881_bib46","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"3","author":"Solomon","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.biopha.2025.118881_bib47","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/eye.2010.147","article-title":"Bevacizumab vs Ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial","volume":"24","author":"Subramanian","year":"2010","journal-title":"Eye (L.)"},{"issue":"1","key":"10.1016\/j.biopha.2025.118881_bib48","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s12886-023-03214-7","article-title":"Comparative efficacy of Aflibercept and Ranibizumab in the treatment of age-related macular degeneration with retinal pigment epithelial detachment: a systematic review and network meta-analysis","volume":"23","author":"Sun","year":"2023","journal-title":"BMC Ophthalmol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118881_bib49","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1007\/s12325-023-02675-y","article-title":"Comparative efficacy, durability and safety of Faricimab in the treatment of diabetic macular edema: a systematic literature review and network meta-analysis","volume":"40","author":"Watkins","year":"2023","journal-title":"Adv. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2025.118881_bib50","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"issue":"September","key":"10.1016\/j.biopha.2025.118881_bib51","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.2147\/DDDT.S383101","article-title":"Progress and challenges of anti-VEGF agents and their sustained-release strategies for retinal angiogenesis","volume":"16","author":"Xu","year":"2022","journal-title":"Drug Des. Dev. Ther."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:40:49Z","timestamp":1781880049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225010753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":51,"alternative-id":["S0753332225010753"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118881","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness and safety landscape of anti-VEGF therapies for neovascular age-related macular degeneration: Insights from a systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118881","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118881"}}